Voyxact (sibeprenlimab-szsi) side effects and precautions

Voyxact (sibeprenlimab-szsi) is a drug used to treat primary immunoglobulin A nephropathy (IgAN), but its use comes with some side effects and precautions.

Common adverse reactions include upper respiratory tract infection and erythema at the injection site. Although these reactions are relatively common, they may have a certain impact on patients' daily life. Therefore, patients need to maintain good communication with their doctors while using Voyxact, report any discomfort in a timely manner, and follow the doctor's instructions for regular check-ups.

First, the major warnings associated with Voyxact include immune suppression and an increased risk of infection. The drug suppresses the immune system by reducing the production of antibodies, which may lead to an increased risk of infection in patients, especially those with pre-existing chronic or recurring infections. In clinical trials, 49% of patients treated with Voyxact developed an infection, compared with 45% of patients in the placebo group. Therefore, patients must be evaluated for active infection before initiating treatment and closely monitored for signs and symptoms of infection during treatment. If a patient develops a serious infection, doctors should consider suspending Voyxact until the infection is under control.

In addition,Clinical research data on the combination of Voyxact and systemic immunosuppressive drugs are limited, so the possible immunosuppressive enhancement effect needs to be carefully considered when used in combination. In this situation, physicians should carefully evaluate the patient's specific situation to decide whether to continue using Voyxact.

Secondly,Voyxact may affect the immune response to vaccines, specifically increasing the risk of live vaccine infection. Therefore, patients are advised to avoid receiving live vaccines within 30 days before starting Voyxact or during treatment. There are currently no data on the transmission of infection from patients receiving live vaccines to patients taking Voyxact, and there is a lack of data on the effectiveness of vaccination while taking Voyxact, further highlighting the risks of vaccination during treatment.

Reference materials:https://go.drugbank.com/drugs/DB18919